Long-term follow-up of cervical dystonia patients treated with botulinum toxin A

Movement Disorders

Volumn 19, Issue 3, 2004, Pages 303-308

  Haussermann, Peter ^a   Marczoch, Stefanie ^a   Klinger, Christiane ^a   Landgrebe, Michael ^a   Conrad, Bastian ^a   Ceballos Baumann, Andres ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Botulinum toxin A; Cervical dystonia; Long term outcome

Indexed keywords

BENZODIAZEPINE; BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT; TIAPRIDE; MUSCLE RELAXANT AGENT;

ACUPUNCTURE; ADULT; ALTERNATIVE MEDICINE; ARTICLE; BLEPHAROSPASM; CONTROLLED STUDY; DEATH; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; DYSTONIA; FEMALE; FOLLOW UP; HUMAN; JAW DISEASE; MAJOR CLINICAL STUDY; MALE; MEIGE DISEASE; MUSCLE CRAMP; MUSCLE WEAKNESS; NECK MUSCLE; NEURECTOMY; PATIENT SATISFACTION; PHYSIOTHERAPY; PRIORITY JOURNAL; PSYCHOTHERAPY; TREATMENT FAILURE; TREATMENT OUTCOME; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRE; TIME; TORTICOLLIS;

ADULT; BOTULINUM TOXIN TYPE A; COHORT STUDIES; DYSTONIC DISORDERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEIGE SYNDROME; MIDDLE AGED; NEUROMUSCULAR AGENTS; QUALITY OF LIFE; QUESTIONNAIRES; TIME FACTORS; TORTICOLLIS;

EID: 3042635460     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10659     Document Type: Article

References (31)

1. Nutt JG, Muenter MD, Melton LJ III, Aronson A, Kurland LT. Epidemiology of dystonia in Rochester, Minnesota. Adv Neurol 1988;50:361-365.
2. Dauer WT, Burke RE, Greene P, Fahn S. Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia. Brain 1998;121:547-560.
3. Hilker R, Schischniaschvili M, Ghaemi M, Jacobs A, Rudolf J. Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia. J Neurol Neurosurg Psychiatry 2001;71:193-199.
4. Camfield L, Ben Shlomo Y, Warner TT. Impact of cervical dystonia on quality of life. Mov Disord 2002;17:838-841.
5. Ben Shlomo Y, Camfield L, Warner T. What are the determinants of quality of life in people with cervical dystonia? J Neurol Neurosurg Psychiatry 2002;72:608-614.
6. Tsui JK, Eisen A, Mak E, Carruthers J, Scott A, Calne DB. A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci 1985;12:314-316.
7. Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 1986;2: 245-247.
8. Brans JW, Lindeboom R, Aramideh M, Speelman JD. Long-term effect of botulinum toxin on impairment and functional health in cervical dystonia. Neurology 1998;50:1461-1463.
9. Blackie JD, Lees AJ. Botulinum toxin treatment in spasmodic torticollis. J Neurol Neurosurg Psychiatry 1990;53:640-643.
10. Greene P, Kang U, Fahn S, Brin M, Moskowitz C, Flaster E. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 1990; 40:1213-1218.
11. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987; 37:616-623.
12. Poewe W, Wissel J. Use of botulinum toxin in the treatment of cervical dystonia. Baillieres Clin Neurol 1993;2:179-185.
13. Poewe W, Deuschl G, Nebe A, Feifel E, Wissel J, Benecke R, et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry 1998;64:13-17.
14. Castelon KE, Trender-Gerhard I, Kamm C, Warner T, Ben Shlomo Y, Gasser T, et al. Service-based survey of dystonia in Munich. Neuroepidemiology 2002;21:202-206.
15. Ceballos-Baumann AO. Evidence-based medicine in botulinum toxin therapy for cervical dystonia. J Neurol 2001;248(Suppl. 1):14-20.
16. Defazio G, Abbruzzese G, Girlanda P, Vacca L, Curra A, De Salvia R, et al. Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Arch Neurol 2002;59:418-420.
17. Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 2002;17: 1288-1293.
18. Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 1999;246: 265-274.
19. Goschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences. Exp Neurol 1997;147:96-102.
20. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994;9:213-217.
21. Greene P, Kang UJ, Fahn S. Spread of symptoms in idiopathic torsion dystonia. Mov Disord 1995;10:143-152.
22. Jankovic J, Leder S, Warner D, Schwartz K. Cervical dystonia: clinical findings and associated movement disorders. Neurology 1991;41:1088-1091.
23. Jahanshahi M, Marion MIL Marsden CD. Natural history of adult-onset idiopathic torticollis. Arch Neurol 1990;47:548-552.
24. Defazio G, Berardelli A, Abbruzzese G, Coviello V, Carella F, De Berardinis MT, et al. Risk factors for spread of primary adult onset blepharospasm: a multicentre investigation of the Italian movement disorders study group. J Neurol Neurosurg Psychiatry 1999; 67:613-619.
25. Lowenstein DH, Aminoff MJ. The clinical course of spasmodic torticollis. Neurology 1988;38:530-532.
26. Goschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies-therapeutic consequences. Exp Neurol 1997;147:96-102.
27. Van den Bergh P, Francart J, Mourin S, Kollmann P, Laterre EC. Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Muscle Nerve 1995;18: 720-729.
28. Krack P, Deuschl G, Benecke R, Ceballos-Baumann AO, Marion MH, Oertel WH, et al. Dose standardization of botulinum toxin. Mov Disord 1998;13:749-751.
29. Jankovic J, Schwartz KS. Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology 1993;43:834-836.
30. Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology 1990;40:277-280.
31. Brashear A, Bergan K, Wojcieszek J, Siemers ER, Ambrosius W. Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A. Mov Disord 2000;15:150-153.